Killing Two Birds With One Stone: Effective Control of Both Non-Small Cell Lung Cancer and Progressive Multifocal Leukoencephalopathy With Atezolizumab, A Case Report

Autor: Nicolas Lambert, Majdouline El Moussaoui, Caroline Ritacco, Martin Moïse, Astrid Paulus, Philippe Delvenne, Frédéric Baron, Bernard Sadzot, Pierre Maquet

Publikováno v: Frontiers in Immunology, Vol 13 (2022)

Treating patients with cancer complicated by severe opportunistic infections is particularly challenging since classical cancer treatments, such as chemotherapy, often induce profound immune suppression and, as a result, may favor infection progressi

Externí odkaz: https://doaj.org/article/fab0976f15114f5f836ff88293b2f520

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab

Autor: Inmaculada Toboso, Amalia Tejeda-Velarde, Roberto Alvarez-Lafuente, Rafael Arroyo, Harald Hegen, Florian Deisenhammer, Susana Sainz de la Maza, José C. Alvarez-Cermeño, Guillermo Izquierdo, Dolores Paramo, Pedro Oliva, Bonaventura Casanova, Eduardo Agüera-Morales, Diego Franciotta, Matteo Gastaldi, Oscar Fernández, Patricia Urbaneja, José M. Garcia-Dominguez, Fernando Romero, Alicia Laroni, Antonio Uccelli, Angel Perez-Sempere, Albert Saiz, Yolanda Blanco, Daniela Galimberti, Elio Scarpini, Carmen Espejo, Xavier Montalban, Ludwig Rasche, Friedemann Paul, Inés González, Elena Álvarez, Cristina Ramo, Ana B. Caminero, Yolanda Aladro, Carmen Calles, Pablo Eguía, Antonio Belenguer-Benavides, Lluis Ramió-Torrentà, Ester Quintana, José E. Martínez-Rodríguez, Agustín Oterino, Carlos López de Silanes, Luis I. Casanova, Lamberto Landete, Jette Frederiksen, Gabriel Bsteh, Patricia Mulero, Manuel Comabella, Miguel A. Hernández, Mercedes Espiño, José M. Prieto, Domingo Pérez, María Otano, Francisco Padilla, Juan A. García-Merino, Laura Navarro, Alfonso Muriel, Lucienne Costa Frossard, Luisa M. Villar

Publikováno v: Frontiers in Neurology, Vol 11 (2020)

Overview: We assessed the role of age and disease activity as new factors contributing to establish the risk of progressive multifocal leucoencephalopathy in multiple sclerosis patients treated with natalizumab in 36 University Hospitals in Europe. W

Externí odkaz: https://doaj.org/article/c82f6fa684d240fe86a6b469a1788aa1

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab

Autor: Friedemann Paul, Angel Perez-Sempere, Oscar Fernandez, Alicia Laroni, Miguel A Hernández, Domingo Pérez, Matteo Gastaldi, Susana Sainz de la Maza, Guillermo Izquierdo, Mercedes Espiño, Gabriel Bsteh, Antonio Belenguer-Benavides, Jose E Martínez-Rodríguez, Eduardo Agüera-Morales, Luisa M. Villar, Inmaculada Toboso, Florian Deisenhammer, Cristina Ramo, Patricia Urbaneja, Laura Navarro, Pedro Oliva, Inés González, J.A. García-Merino, Bonaventura Casanova, Ludwig Rasche, Albert Saiz, Agustín Oterino, Antonio Uccelli, Daniela Galimberti, J.C. Álvarez-Cermeño, Manuel Comabella, Carmen Espejo, Jette L. Frederiksen, Harald Hegen, J.M. Prieto, José M. García-Domínguez, Francisco Padilla, Luis I Casanova, Xavier Montalban, Carmen Calles, Lamberto Landete, Diego Franciotta, Ester Quintana, Patricia Mulero, Elio Scarpini, Rafael Arroyo, Roberto Alvarez-Lafuente, Fernando Romero, Yolanda Aladro, Amalia Tejeda-Velarde, Alfonso Muriel, Lucienne Costa Frossard, Lluís Ramió-Torrentà, María Otano, Yolanda Blanco, Carlos López de Silanes, Dolores Paramo, Elena Álvarez, Ana B Caminero, Pablo Eguía

Publikováno v: Frontiers in Neurology
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
Toboso, I, Tejeda-Velarde, A, Alvarez-Lafuente, R, Arroyo, R, Hegen, H, Deisenhammer, F, Sainz de la Maza, S, Alvarez-Cermeño, J C, Izquierdo, G, Paramo, D, Oliva, P, Casanova, B, Agüera-Morales, E, Franciotta, D, Gastaldi, M, Fernández, O, Urbaneja, P, Garcia-Dominguez, J M, Romero, F, Laroni, A, Uccelli, A, Perez-Sempere, A, Saiz, A, Blanco, Y, Galimberti, D, Scarpini, E, Espejo, C, Montalban, X, Rasche, L, Paul, F, González, I, Álvarez, E, Ramo, C, Caminero, A B, Aladro, Y, Calles, C, Eguía, P, Belenguer-Benavides, A, Ramió-Torrentà, L, Quintana, E, Martínez-Rodríguez, J E, Oterino, A, López de Silanes, C, Casanova, L I, Landete, L, Frederiksen, J, Bsteh, G, Mulero, P, Comabella, M, Hernández, M A, Espiño, M, Prieto, J M, Pérez, D, Otano, M, Padilla, F, García-Merino, J A, Navarro, L, Muriel, A, Frossard, L C & Villar, L M 2020, ' New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab ', Frontiers in Neurology, vol. 11, 579438 . https://doi.org/10.3389/fneur.2020.579438
Frontiers in Neurology, Vol 11 (2020)
Frontiers in neurology
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe

Overview: We assessed the role of age and disease activity as new factors contributing to establish the risk of progressive multifocal leucoencephalopathy in multiple sclerosis patients treated with natalizumab in 36 University Hospitals in Europe. W

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef36835f42e2ef0f7c67c0021ce9224e
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=8697

Case Report: Findings Suggestive of Paraclinical Progressive Multifocal Leukoencephalopathy and Lung Cancer-Derived Brain Metastases in an MS Patient Treated With Fingolimod

Autor: Maass, Fabian, von Gottberg, Philipp, Franz, Jonas, Stadelmann, Christine, Bähr, Mathias, Weber, Martin S.

Publikováno v: Frontiers in Neurology

Fingolimod represents a highly effective disease-modifying drug in patients with active relapsing-remitting multiple sclerosis (RRMS). Its immunosuppressive effects can mediate adverse events like increased risk of cancer development or appearance of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::d2b45298771f8a5dfefdd41a55efa395